SCHEMBL484713

SCHEMBL484713

FC(F)(F)c1cnc(N2CCC3(CCNC3)CC2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 6/20 0.51
CYP3A4 P08684 5/20 0.51
TSHR P16473 3/20 0.51
ALDH1A1 P00352 4/20 0.45
HSD17B10 Q99714 4/20 0.45
CYP1A2 P05177 2/20 0.45
CYP11B1 P15538 1/20 0.43
CYP2C9 P11712 3/20 0.41
USP2 O75604 2/20 0.41
NPY2R P49146 1/20 0.39
ROCK2 O75116 1/20 0.39
ROCK1 Q13464 1/20 0.39
CDC42BPB Q9Y5S2 1/20 0.39
CYP2C19 P33261 2/20 0.39
HPGD P15428 2/20 0.39
PARP1 P09874 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A4 P31645 1/20 0.38
SLC6A3 Q01959 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30327820 0.84 CYP2D6 (0.52) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL485461 0.82 KCNH2 (0.48) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL485095 0.79 CYP2D6 (0.81) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
SCHEMBL3922344 0.78 ALDH1A1 (0.53) ALDH1A1USP2PARP1SMN1; SMN2OGA
SCHEMBL31239676 0.77 HSD17B10 (0.40) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL17541517 0.77 ALDH1A1 (0.56) ALDH1A1USP2SMN1; SMN2OGA
Hydrochloric Acid SCHEMBL21522534 0.77 ALDH1A1 (0.56) ALDH1A1USP2SMN1; SMN2OGA
SCHEMBL14996529 0.77 CYP3A4 (0.43) CYP2D6CYP3A4TSHRHSD17B10CYP1A2
SCHEMBL485117 0.77 CYP2D6 (0.51) CYP2D6CYP3A4TSHRALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL25309482 0.76 HSD17B10 (0.39) CYP2D6CYP3A4TSHRALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF NOVOSTAR PHARMACEUTICALS, LTD. (CN) 2024-10-10 US disclosed
CN-115785074-B PARP7 inhibitors and uses thereof 诺沃斯达药业(上海)有限公司 2024-05-07 CN disclosed
EP-4338737-A1 PARP7 INHIBITOR AND USE THEREOF Novostar Pharmaceuticals, Ltd. (CN) 2024-03-20 EP disclosed
WO-2023185073-A1 PARP7 INHIBITOR AND USE THEREOF 诺沃斯达药业(上海)有限公司 2023-10-05 WO disclosed
CN-115785074-A PARP7 inhibitors and uses thereof 诺沃斯达药业(上海)有限公司 2023-03-14 CN disclosed
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
EP-2411381-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-02-01 EP disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 WO disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231327-A1 Substituted Spiro-Amide Compounds BDKRB1, BDKRB2, REN CYP2D6 1926/4885CYP3A4 3781/4885TSHR 338/4885
US-20240336596-A1 PARP7 INHIBITOR AND USE THEREOF PARP1, PARP3, PARP11 CYP2D6 1034/4885CYP3A4 1830/4885TSHR 4608/4885
US-20100249095-A1 Substituted Spiro-amide Compounds BDKRB1, BDKRB2, REN CYP2D6 1926/4885CYP3A4 3781/4885TSHR 338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.